Fig. 1

(a) Cell viability (%) against Doxorubicin (µM).

(b) Cell viability (%) against Cisplatin (µM).

(c) Cell viability (%) against Carboplatin (µM).

(d) Cell viability (%) against Oxaliplatin (µM).